Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: A prospective screening study with a 20-year follow-up

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Cao, Su Mei ^a   Liu, Zhiwei ^a   Jia, Wei Hua ^a   Huang, Qi Hong ^b   Liu, Qing ^a   Guo, Xiang ^a   Huang, Teng Bo ^a   Ye, Weimin ^c   Hong, Ming Huang ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Sihui Cancer Institute   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; VIRUS CAPSID ANTIGEN; CAPSID PROTEIN; EPSTEIN BARR VIRAL CAPSID ANTIGEN; EPSTEIN-BARR VIRAL CAPSID ANTIGEN; IMMUNOGLOBULIN A; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY TITER; ANTIGENIC VARIATION; ARTICLE; CANCER RISK; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEROLOGY; BLOOD; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; NASOPHARYNX TUMOR; VIROLOGY;

HUMAN HERPESVIRUS 4; MIRIDAE;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; MALE; NASOPHARYNGEAL NEOPLASMS;

EID: 79955548008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019100     Document Type: Article

References (62)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Chang ET, Adami HO, (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777.
3. Jia WH, Huang QH, Liao J, Ye W, Shugart YY, et al. (2006) Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer 6: 178.
4. Saika K, Sobue T, (2008) Comparison of time trends in cancer incidence (1973-2002) in Asia, from Cancer Incidence in Five Continents Vols IV-IX. Jpn J Clin Oncol 38: 872-873.
5. Yu MC, Yuan JM, (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12: 421-429.
6. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, et al. (1994) Preserved foods and nasopharyngeal carcinoma: a case-control study among Singapore Chinese. Int J Cancer 59: 585-590.
7. Yu MC, Henderson BE, (1987) Intake of Cantonese-style salted fish as a cause of nasopharyngeal carcinoma. IARC Sci Publ pp. 547-549.
8. Yu MC, Ho JH, Lai SH, Henderson BE, (1986) Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res 46: 956-961.
9. Yu MC, Mo CC, Chong WX, Yeh FS, Henderson BE, (1988) Preserved foods and nasopharyngeal carcinoma: a case-control study in Guangxi, China. Cancer Res 48: 1954-1959.
10. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, et al. (2000) Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int J Cancer 85: 358-363.
11. Lanier AP, Bornkamm GW, Henle W, Henle G, Bender TR, et al. (1981) Association of Epstein-Barr virus with nasopharyngeal carcinoma in Alaskan native patients: serum antibodies and tissue EBNA and DNA. Int J Cancer 28: 301-305.
12. Niedobitek G, (2000) Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol 53: 248-254.
13. Niedobitek G, Agathanggelou A, Nicholls JM, (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 7: 165-174.
14. Niedobitek G, Hansmann ML, Herbst H, Young LS, Dienemann D, et al. (1991) Epstein-Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus. J Pathol 165: 17-24.
15. Niedobitek G, Young LS, Sam CK, Brooks L, Prasad U, et al. (1992) Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol 140: 879-887.
16. Plaza G, Manzanal AI, Fogue L, Santon A, Martinez-Montero JC, et al. (2002) Association of Epstein-Barr virus and nasopharyngeal carcinoma in Caucasian patients. Ann Otol Rhinol Laryngol 111: 210-216.
17. Raab-Traub N, (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12: 431-441.
18. Wolf H, zur Hausen H, Becker V, (1973) EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol 244: 245-247.
19. Zheng X, Yan L, Nilsson B, Eklund G, Drettner B, (1994) Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol 33: 867-872.
20. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F, et al. (2002) Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 31: 395-399.
21. Lo KW, Huang DP, (2002) Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 12: 451-462.
22. Li X, Fasano R, Wang E, Yao KT, Marincola FM, (2009) HLA associations with nasopharyngeal carcinoma. Curr Mol Med 9: 751-765.
23. Lu SJ, Day NE, Degos L, Lepage V, Wang PC, et al. (1990) Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 346: 470-471.
24. Liu T, (1999) Issues in the management of nasopharyngeal carcinoma. Crit Rev Oncol Hematol 31: 55-69.
25. Old LJ, Boyse EA, Oettgen HF, Harven ED, Geering G, et al. (1966) Precipitating Antibody in Human Serum to an Antigen Present in Cultured Burkitt's Lymphoma Cells. Proc Natl Acad Sci U S A 56: 1699-1704.
26. Lung ML, Chan KH, Lam WP, Kou SK, Choy D, et al. (1989) In situ detection of Epstein-Barr virus markers in nasopharyngeal carcinoma patients. Oncology 46: 310-317.
27. Raab-Traub N, Flynn K, Pearson G, Huang A, Levine P, et al. (1987) The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer 39: 25-29.
28. Murray PG, Niedobitek G, Kremmer E, Grasser F, Reynolds GM, et al. (1996) In situ detection of the Epstein-Barr virus-encoded nuclear antigen 1 in oral hairy leukoplakia and virus-associated carcinomas. J Pathol 178: 44-47.
29. Young LS, Dawson CW, Clark D, Rupani H, Busson P, et al. (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69 (Pt 5): 1051-1065.
30. Ayadi W, Karray-Hakim H, Feki L, Khabir A, Boudawara T, et al. (2009) IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients. J Med Virol 81: 1412-1421.
31. Brooks L, Yao QY, Rickinson AB, Young LS, (1992) Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66: 2689-2697.
32. Kung CP, Meckes DG Jr, Raab-Traub N, (2011) EBV Latent Membrane Protein 1 (LMP1) activates EGFR, STAT3 and ERK through effects on PKC{delta}. J Virol.
33. Morris MA, Dawson CW, Young LS, (2009) Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol 5: 811-825.
34. You S, Zhang F, Meng F, Li H, Liu Q, et al. (2011) EBV-encoded LMP1 increases nuclear beta-catenin accumulation and its transcriptional activity in nasopharyngeal carcinoma. Tumour Biol.
35. Henle G, Henle W, (1976) Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17: 1-7.
36. Lanier A, Bender T, Talbot M, Wilmeth S, Tschopp C, et al. (1980) Nasopharyngeal carcinoma in Alaskan Eskimos Indians, and Aleuts: a review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. Cancer 46: 2100-2106.
37. Lanier AP, Henle W, Bender TR, Henle G, Talbot ML, (1980) Epstein-Barr virus-specific antibody titers in seven Alaskan natives before and after diagnosis of nasopharyngeal carcinoma. Int J Cancer 26: 133-137.
38. Paramita DK, Fatmawati C, Juwana H, van Schaijk FG, Fachiroh J, et al. (2011) Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. J Med Virol 83: 665-678.
39. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, et al. (2001) Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 345: 1877-1882.
40. Hsu WL, Chen JY, Chien YC, Liu MY, You SL, et al. (2009) Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Cancer Epidemiol Biomarkers Prev 18: 1218-1226.
41. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, et al. (2007) Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 96: 623-630.
42. Yi Z, Yuxi L, Chunren L, Sanwen C, Jihneng W, et al. (1980) Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology 13: 162-168.
43. Zeng Y, Pi GH, Deng H, Zhang JM, Wang PC, et al. (1986) Epstein-Barr virus seroepidemiology in China. AIDS Res 2 (Suppl 1): S7-15.
44. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, et al. (1982) Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 29: 139-141.
45. Zeng Y, Zhong JM, Li LY, Wang PZ, Tang H, et al. (1983) Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology 20: 190-194.
46. Ng MH, Chan KH, Ng SP, Zong YS, (2006) Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma. Ai Zheng 25: 250-256.
47. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, et al. (1992) Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69: 3-7.
48. Chan KH, Gu YL, Ng F, Ng PS, Seto WH, et al. (2003) EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 105: 706-709.
49. Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, et al. (2007) Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma. J Med Virol 79: 1710-1721.
50. Tang JW, Rohwader E, Chu IM, Tsang RK, Steinhagen K, et al. (2007) Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma. J Clin Virol 40: 284-288.
51. Hsu WL, Yu KJ, Chien YC, Chiang CJ, Cheng YJ, et al. (2011) Familial tendency and risk of nasopharyngeal carcinoma in taiwan: effects of covariates on risk. Am J Epidemiol 173: 292-299.
52. Wei WI, Sham JS, (2005) Nasopharyngeal carcinoma. Lancet 365: 2041-2054.
53. Cao SM, Simons MJ, Qian CN, (2011) The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 30: 114-119.
54. An X, Wang FH, Ding PR, Deng L, Jiang WQ, et al. (2011) Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer.
55. Horikawa T, Yoshizaki T, Kondo S, Furukawa M, Kaizaki Y, et al. (2011) Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br J Cancer.
56. Sixbey JW, Yao QY, (1992) Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 255: 1578-1580.
57. Pearson GR, Vroman B, Chase B, Sculley T, Hummel M, et al. (1983) Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol 47: 193-201.
58. Sun Y, Li JL, Ye YZ, Xiao XB, Zhang CQ, et al. (1996) Preparation of a Quality Control Assay for IgA-EA by Heating Method (in Chinese). Clinical Medicine and Health pp. 360-361.
59. Ye YZ, Sun Y, Li JL, Xiao XB, Zhang CQ, et al. (1997) Preparation and Application of a Stable Quality Control Assay for testing IgA-VcA (in Chinese). Ai Zheng 16: 79-80.
60. Schoenfeld D, (1982) Partial Residuals for the Proportional Hazards Regression-Model. Biometrika 69: 239-241.
61. Heagerty PJ, Lumley T, Pepe MS, (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344.
62. Zheng Y, Cai T, Feng Z, (2006) Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics 62: 279-287.